Sobrera is a clinical phase biopharma company developing new treatments for patients with substance use disorders.
Sobrera is a Swedish biopharma company developing new treatments for patients with substance use disorders. It is based on research from the Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, University of Gothenburg. The inventors are Prof. Bo Söderpalm and Dr. Andrea de Bejczy. They have substantial experience of research in alcohol abuse and in managing clinical studies in Alcohol Use Disorders (AUD).
Our focus is on SO-001, a new therapy for AUD where there is a large unmet medical need. Alcohol Use Disorder is a major global health issue and a major cause of mortality and morbidity. Available treatments for AUD are moderately effective and improved treatments are much needed.
A clinical phase II randomized controlled trial is ongoing, examining the effects and safety of the new therapy in patients with moderate to severe alcohol use disorder.
Mission and Value proposition
Provide highly effective and widely used treatments reducing the medical and social consequences of substance use disorders.
To make life better for a large group of patients suffering from substance use disorders and other mental conditions